Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Novartis solid tumor ‘CAR T cell’ still holds promise: researcher

(Reuters) – A new type of immuno-oncology treatment from Novartis AG proved safe in a tiny study of three types of solid tumors, but the trial included too few patients and used too small a dose of the experimental product to prove effectiveness, according to data presented at a cancer meeting on Sunday. The so-called […]

Read More »

Extending Treatment Up To Eight Weeks With Infusion Medication Shown Safe And Effective In Patients With Multiple Sclerosis

NEW YORK, April 20, 2015 /PRNewswire-USNewswire/ — Extending the dose of an infusion medication for multiple sclerosis (MS) from 4 weeks up to 8 has been shown to be well-tolerated and effective — and resulted in no cases of the potentially fatal side effect, progressive multifocal leukoencephalopathy (PML), according to a new study led by researchers […]

Read More »

Merck Cancer Drug Shines Against Skin, Lung Cancer

Merck’s immune-boosting cancer drug, Keytruda, bested the standard of care in advanced melanoma, the deadly skin cancer, and showed promising results in non-small cell lung cancer. Based on these data, Merck says it has filed an application with the Food and Drug Administration for Keytruda to be used in non-small cell lung cancer, and will soon […]

Read More »

Long Term, Regular Aspirin Use May Reduce Cancer Risk, Harvard School of Public Health Study

Long-term, Regular Aspirin Use Modestly Decreased Cancer Risk PHILADELPHIA — Long-term, regular aspirin use was associated with a modestly reduced overall risk for cancer driven primarily by a reduction in the risk for colorectal cancers, according to research presented here at the AACR Annual Meeting 2015 , April 18-22. “Previous studies of aspirin and cancer […]

Read More »

Broccoli Sprout May Prevent Head and Neck Cancer, University of Pittsburgh Cancer Institute (UPCI) Study

Broccoli Sprout Extract Promising For Head And Neck Cancer Prevention PHILADELPHIA, April 19, 2015 – Broccoli sprout extract protects against oral cancer in mice and proved tolerable in a small group of healthy human volunteers, the University of Pittsburgh Cancer Institute (UPCI), partner with UPMC CancerCenter, announced today at the American Association for Cancer Research […]

Read More »

Baxter International’s Bleeding Disorder Drug Delivers 100 % Percent Success Rate in Late-Stage Study

DEERFIELD, Ill.–(BUSINESS WIRE)–Baxter International Inc. (NYSE:BAX) today presented additional data from the Phase III clinical trial of BAX 111, the first highly-purified recombinant von Willebrand Factor (rVWF) in clinical development as a treatment for patients with von Willebrand disease, the most common type of inherited bleeding disorder.1 The data were presented as an Abstract of […]

Read More »

Brain Scans Give Clues to Link Between Alzheimer’s, Down Syndrome, /i> Reveals

It’s long been known that people with Down syndrome are at higher risk for Alzheimer’s disease. Now, research suggests that changes in the brains of people with Down syndrome, as seen on brain scans, might help lead to promising treatments that could delay or prevent Alzheimer’s. “We and other researchers have been interested in detecting […]

Read More »

Merck’s Keytruda shrinks lung cancer tumors, FDA approval sought

Merck & Co Inc’s Keytruda, approved for treating melanoma, was shown in a trial to shrink tumors in nearly half of advanced lung cancer patients with high levels of a protein used by tumors to evade the body’s own disease-fighting cells. The company said it has filed for U.S. Food and Drug Administration approval of […]

Read More »

KEYTRUDA, Merck’s Anti-PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival and Overall Response Rate Compared to Ipilimumab an Anti-CTLA-4 Therapy…

PHILADELPHIA–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the randomized, pivotal Phase 3 study, KEYNOTE-006, in the treatment of unresectable advanced melanoma. In the study, KEYTRUDA® (pembrolizumab) was statistically superior to ipilimumab for progression-free survival (PFS), overall survival (OS), and overall response rate (ORR). On March 24, […]

Read More »

Early Findings with KEYTRUDA, Merck’s Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting

PHILADELPHIA–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in 25 patients with advanced pleural mesothelioma, a difficult-to-treat cancer of the lining of the lungs, abdomen and other organs. The early findings presented showed an […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom